Loading stock data…
SYK
$295.25+4.37 (+1.50%)
Pre-Market$295.42+0.17 (+0.06%)· Last close May 5
Stryker Corporation operates as a medical technology company in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stryker Corporation in the Healthcare sector is trading at $295.25. The stock is currently near its 52-week low of $290.22, remaining 18.4% below its 200-day moving average. Technical signals show oversold RSI of 18 and bearish MACD signal, explaining why SYK maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 18) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$295.25
Potential Downside
46%
Whystock Fair Value$159.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus26 analysts
Buy
Mean target$394.12+33.5%
Range$315.00 – $465.00
Fundamentals
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$124.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.17%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.48%
Volume
Today's trading volume
2.99M
Recent News
UFP Tech (UFPT) Q2 2025 Earnings Transcript
R. Jeffrey Bailly: Thank you, Ron, and thank you to everyone joining the call. UFP had a strong second quarter. Revenue from our two largest customers, Intuitive Surgical and Stryker, grew 10% and 567%, respectively.
Stryker Q1 Earnings Call Highlights
Stryker (NYSE:SYK) executives said the company’s first quarter results were meaningfully disrupted by a late-quarter cyber incident that temporarily halted production and delayed shipments and revenue recognition, but management maintained its full-year outlook as operations returned to normal in ea
Stryker maintains FY26 outlook despite cyberattack-impacted Q1
Stryker was hit by a cyberattack that caused widespread disruption to its operations on 11 March 2026.
Stryker Q1 Earnings & Sales Miss Estimates on Cyber Disruption
SYK misses Q1 earnings and revenue estimates as a cyber incident disrupts production, dents margins, and slows growth despite gains across key segments.
Stryker Corporation Q1 2026 Earnings Call Summary
Moby summary of Stryker Corporation's Q1 2026 earnings call